期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 12, 期 1, 页码 113-118出版社
INFORMA HEALTHCARE
DOI: 10.1517/14712598.2012.642359
关键词
asthma; benralizumab; IL-5; IL-5R alpha; MEDI-563
资金
- National Center for Research Resources, National Institutes of Health [UL1RR029876]
Introduction: Benralizumab is a monoclonal antibody that binds the a subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据